Core Capital Management & Research, inc.’s Medline Inc MDLN Stock Holding History

Core Capital Management & Research, inc.’s Portfolio MDLN Stock Details MDLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83.9K	Buy	+2,435	New	+$98.1K	0.04%	105

Other funds holding MDLN

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

HFCIX

H&F Corporate Investors X San Francisco, California $2.8B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Core Capital Management & Research, inc.'s MDLN Position: Q2 2026 in Review

Core Capital Management & Research, inc. opened a new position in Medline Inc (MDLN) in Q2 2026: 2,435 shares worth $83.9K. The stake represents 0.04% of the portfolio and ranks #105 among its holdings.

407 funds tracked by Wall St. Rank hold MDLN as of Q2 2026.

Core Capital Management & Research, inc. held 2,435 shares of Medline Inc worth $83.9K as of Q2 2026.
Medline Inc was a new Core Capital Management & Research, inc. position in Q2 2026.
Medline Inc made up 0.04% of Core Capital Management & Research, inc.'s portfolio in Q2 2026, its #105 holding.
407 funds tracked by Wall St. Rank held Medline Inc as of Q2 2026.

Based on Core Capital Management & Research, inc.'s 13F filing for Q2 2026, filed 9 Sep 2026.